Routine Yearly Prostate Cancer Assessment Not As Effectual In Cancer Diagnosis

The New Mayo Clinic research examines the relationship between PSA or prostate specific antigen and size of the prostate. The research discovered that the regular yearly prostate cancer evaluation is not essentially a forecaster for the progress of prostate cancer. Yet, the study proposes that in case the PSA levels are swiftly increasing, it is logical to undergo a prostate biopsy for ascertaining the presence of prostate cancer.

The presentation of these findings by Mayo Clinic was put forth at the North Central Section of the American Urological Association in Scottsdale, Ariz. The findings were derived from a vast group study of men residing in Olmsted County, Minn. The researchers arbitrarily picked 616 men in the age groups of 40-79 years that didn’t suffer from prostate disease. The patients were entrants for assessments in a 2-yearly interval time period lasting for a span of seventeen years that comprised of PSA testing and measuring prostate volume employing ultrasound for ascertaining variations in prostate disease.

Rodney Breau, M.D., a Mayo Clinic urologic oncology member who headed the study stated that one of the crucial benefits of this vast group study is that the men have taken part in the study that lasted for seventeen years. Due to the long-drawn nature of the study, the researchers had the chance to scrutinise the protracted association in-between prostate development, variation in PSA and how prostate cancer develops.

From the 616 men under the study, prostate cancer was observed to develop in about 9.4%, i.e., 58 men. Men detected with prostate cancer had a swifter rate of increase in PSA levels, i.e., 6 % annually in comparison to the men not detected with prostate cancer (3.3% annually). But, the enlargement in prostate size was analogous between these two sets with a median variation of 2.2% annually.

PSA is a substance manufactured in the prostate gland. Usually, minute quantities of PSA make an entry in the blood stream. An elevated level of PSA or a sudden surge in amounts of PSA could suggest the likelihood of cancer.

Dr. Breau stated that their quest was to find solutions to the query about whether surging PSA levels could be elucidated by a comparative rise in prostate size. He further stated that their data suggested that men irrespective of the presence or absence of prostate cancer had analogous rates of prostate growth. In case the PSA levels are rapidly increasing, then a prostate biopsy would be needed for determining the presence of prostate cancer. He pointed out that evaluation of change in the size of the prostate must not have an influence on the choice to undergo biopsy.

Popularity: 3% [?]